A REVIEW OF DISSOLUTION TESTING IN PHARMACEUTICALS AND BIOTECHNOLOGY

Nikhil Rameshvar Kale, Samrat Dinesh Raut, Amit Sukhdev Ghule, Om Ramesh Thorat.
Gajanan Maharaj College of Pharmacy Chh.Sambhajinagar
nikhilkale14244@gmail.com
Dr. Kavita Kulkarni (PhD.Mpharm), Department of Quality Assurance
Gajanan Maharaj College of Pharmacy Chh. Sambhajinagar

Abstract

Dissolution testing is an indispensable analytical technique in the pharmaceutical industry, serving as a critical measure of the release profiles of solid dosage forms, such as tablets and capsules, and their consequent bioavailability. Recognized for its significant impact on drug absorption and clinical effectiveness, the importance of dissolution analysis has led to its widespread use in drug product development, manufacturing, and regulatory assessments. This chapter provides a comprehensive review of dissolution testing, highlighting its evolution, methodologies, applications, and challenges.

The chapter explores various dissolution apparatus defined by the USP, focusing on the most common methods: USP Apparatus 1 (Basket Method) and USP Apparatus 2 (Paddle Method). Each apparatus is examined in detail, covering its design, operational principles, and specific applications tailored to different pharmaceutical formulations. For instance, the Basket Method is ideal for solid dosage forms that float or disintegrate slowly, while the Paddle Method is more versatile and widely used for immediate-release tablets.

Key variables influencing dissolution testing, such as agitation speed, temperature, pH of the dissolution medium, sample volume, and sink conditions, are critically examined. Understanding these variables is essential for ensuring accurate, reliable, and reproducible results in dissolution studies.

Finally, the chapter introduces the Biopharmaceutical Classification System (BCS), which categorizes drugs based on their solubility and permeability characteristics. This system plays a significant role in dissolution testing, particularly for BCS Class II (low solubility, high permeability) and Class III (high solubility, low permeability) drugs, where dissolution testing becomes vital for assessing formulation adjustments and predicting in vivo performance.

In conclusion, this chapter provides a detailed overview of dissolution testing, its historical significance, methodological advancements, and regulatory considerations, emphasizing its crucial role in ensuring drug quality and improving bioavailability predictions. The ongoing challenges in simulating in vivo conditions for dissolution testing highlight the need for continued research and innovation in this essential area of pharmaceutical science.

Keyword-*Dissolution testing , Pharmaceutical dosage forms, Biopharmaceutical classification system (BCS), USP Apparatus, Bioavailability.*

Introduction.

Dissolution analysis has long been recognized for its significant influence on bioavailability and clinical outcomes, making it a critical test in the development, manufacturing, and regulatory evaluation of pharmaceutical products. This test not only provides insights into the rate and extent of drug absorption but also examines how biopharmaceutical characteristics and formulation principles impact the release profile of a drug product. Despite its extensive application across the pharmaceutical industry and regulatory bodies, a comprehensive understanding of dissolution testing's fundamental principles and applications remains elusive. The

purpose of this chapter is to provide a succinct review of dissolution methods used for quality control (QC) and bioavailability evaluations, discuss the issues related to their application and limitations, and address the challenges of refining current methods, particularly those employed for assessing a drug product's in vivo performance. The chapter is organized as follows: it begins with background information on dissolution, its role in drug absorption, the underlying theories, and the factors influencing dissolution testing. The next section explores the present roles of dissolution testing, followed by an assessment of its value and constraints as a QC tool in the current industrial landscape. The chapter concludes with a discussion on the biopharmaceutics classification system (BCS) and biorelevant dissolution methods.

Historically, pharmaceutical dosage forms primarily included injections, oral formulations such as solutions, suspensions, tablets, and capsules, as well as topical creams and ointments. However, advances in drug delivery technologies have led to the development of novel dosage forms designed to address the limitations associated with traditional delivery systems. Research has increasingly focused on non-oral alternatives for drugs unsuitable for oral administration. These alternative delivery routes include buccal, sublingual, nasal, pulmonary, and vaginal pathways, which can provide localized drug delivery or systemic entry while minimizing first-pass metabolism and potential systemic side effects. Dissolution testing plays a vital role in predicting the in vivo behavior of these dosage forms, but the conventional dissolution media used in QC testing often fail to replicate the complex physiological conditions associated with common routes of administration, leading to challenges in establishing in vivo correlations. To predict how dosage forms will behave at the primary absorption sites, it is essential to accurately simulate in vivo conditions. This chapter also outlines the characteristics of various drug administration routes, including parenteral, oral, buccal, sublingual, pulmonary, ophthalmic, and vaginal, which must be considered when developing simulated dissolution media. It provides a comprehensive compilation of various simulated biological fluids, such as simulated sweat, that can be used in dissolution testing.

Dissolution testing is a critical analytical method used to evaluate drug release profiles from pharmaceutical products, particularly solid oral dosage forms like tablets and capsules. For these forms to be effective, the drug must be released and typically dissolved in gastrointestinal fluids. This testing serves several purposes, including routine quality control, product characterization, confirmation of product consistency following scale-up and post-approval changes (SUPAC), and waivers for bioequivalence requirements in lower-strength formulations and other instances.

History

EVOLUTION OF DRUG DISSOLUTION TESTING

The first dissolution studies were reported in the literature in 1897 by Noyes and Whitney, where they studied the dissolution of two sparingly soluble compounds, namely benzoic acid and lead chloride. The chemical substances were laid around glass

cylinders that were submerged into vessels containing water. These cylinders were rotated at constant speed and were held under constant temperature. Their fundamental work led to the well-known equation in physical pharmacy, the Noyes–Whitney equation. Even though there was a lot of activity investigating dissolution from the physical–chemical point of view, it was not until the early 1950s that pharmaceutical scientists started to realize the importance of dissolution on the rate of absorption of orally administered drugs. Edwards, in 1951, postulated that the rate-limiting step in the absorption of aspirin in the bloodstream was its dissolution. In 1957, Nelson was the first scientist to explicitly relate the blood levels of orally administered theophylline to Its dissolution.

However, in the mid-1960s, the realization of the impact of dissolution on the therapeutic effect of orally administered drugs began. Reports published in the early 1960s drew attention to the lack of efficacy of two brands of tolbutamide marketed in Canada. Tablets with much slower disintegration and release characteristics showed a marked decrease in plasma levels. Such observations were confirmed with other products such as chloramphenicol and diphenylhydantoin. In 1971, Lindenbaum observed a seven-fold difference in digoxin serum levels among the different digoxin formulations. This finding prompted the FDA to investigate the dissolution of 44 lots of digoxin from 32 different manufacturers. The study revealed a wide difference in in vitro release characteristics of the different lots, thus explaining the observed bioinequivalence. In the case of phenytoin, increased toxicities were observed when the manufacturer replaced calcium sulfate with lactose. This resulted in higher concentrations due to a faster dissolution rate attributed to the more hydrophilic nature of lactose compared with calcium sulfate.

The net outcome of all the above cases was the introduction of dissolution requirements by both the FDA and USP. As a result, the dissolution test became a quality control tool to ensure lot-to-lot consistency. In 1971, the basket-stirred flask test (USP Apparatus 1) was adopted as an official dissolution test in six monographs. In 1978, the paddle method (USP Apparatus 2) was introduced, and a general chapter on drug release was published in USP 21 in 1985. In 1991, the reciprocating cylinder (USP Apparatus 3) for modified-release formulations and, in 1995, the flow-through cell (USP Apparatus 4) for extended-release formulations were adopted. Currently, there are seven official apparatus described in the UPS

Material and Methods of Dissolution Test

Dissolution Testing: Methods and Materials

Dissolution testing is a key quality control measure in the pharmaceutical industry. It is used to measure the rate at which an active pharmaceutical ingredient (API) is released from a solid dosage form (such as a tablet or capsule) into a dissolution medium. This process mimics the release of the drug in the gastrointestinal (GI) tract, providing insight into its bioavailability. This test helps ensure that the product performs consistently and is critical for

drug development, quality control, and regulatory compliance.

The following sections provide a detailed overview of the methods and materials used in dissolution testing, covering the equipment, apparatus, techniques, and analytical methods.

1. Dissolution Apparatus

The United States Pharmacopeia (USP) defines several types of apparatus that are used for dissolution testing. The most common ones are USP Apparatus 1 (Basket Method) and USP Apparatus 2 (Paddle Method). Other apparatus are also used for specialized formulations such as extended-release tablets, suspensions, and transdermal systems.

1.1 USP Apparatus 1: Basket Method

Design: The basket method uses a cylindrical wire mesh basket, usually made of stainless steel, attached to the end of a shaft. The dosage form (tablet or capsule) is placed inside the basket.



Operation: The basket rotates at a controlled speed (e.g., 50-100 RPM) within a dissolution medium (typically 900 mL) contained in a vessel. The medium is kept at a constant temperature of 37°C to simulate human body temperature.

Application: This method is ideal for solid dosage forms that float on the dissolution medium or disintegrate slowly, such as capsules.

1.2 USP Apparatus 2: Paddle Method

Design: In the paddle method, the dosage form is placed at the bottom of a vessel, and a flat-bladed paddle is positioned above it. The paddle rotates at a pre-set speed to agitate the dissolution medium.



Operation: The vessel is filled with a dissolution medium (usually 900 mL), and the paddle stirs the medium at controlled speeds, typically 50-100 RPM. The temperature is maintained at 37°C.

Application: This method is most commonly used for immediate-release tablets and is more versatile compared to the basket method.

1.3 USP Apparatus 3: Reciprocating Cylinder

Design: The reciprocating cylinder apparatus consists of a set of vertically reciprocating cylinders that move up and down in the dissolution medium.

Operation: Dosage forms are placed inside the cylinders, which are transferred between media of different pH (simulating gastric to intestinal transitions) over time.

Application: It is ideal for modified-release formulations and allows for testing of drug release in multiple environments.

1.4 USP Apparatus 4: Flow-Through Cell

Design: The flow-through cell apparatus is a closed system where the dissolution medium continuously flows through a chamber containing the dosage form.

Operation: The medium flows at a controlled rate through the cell, which can be adjusted to simulate different physiological conditions.

Application: This method is particularly useful for testing poorly soluble drugs and formulations like powders, suspensions, or implants.

1.5 USP Apparatus 5: Paddle Over Disk

Design: This method is similar to the paddle method but is specifically adapted for testing transdermal drug delivery systems (TDDS).

Operation: The transdermal patch is placed on a disk that is attached to the bottom of the dissolution vessel, and a paddle stirs the medium above it.

Application: Ideal for testing the release of drugs from transdermal patches.

1.6 USP Apparatus 6: Cylinder

Design: Similar to Apparatus 5, the cylinder apparatus uses a rotating cylinder to agitate the dissolution medium.

Application: This apparatus is particularly suited for slow-dissolving transdermal systems.

1.7 USP Apparatus 7: Reciprocating Holder

Design: This apparatus involves a reciprocating movement of the dosage form between different media.

Operation: The system is used for formulations requiring exposure to different pH environments, mimicking the conditions in various parts of the GI tract.

Application: Mainly used for modified-release dosage forms.

2 Dissolution Media

The dissolution medium is a critical factor in dissolution testing. It mimics the physiological conditions of the GI tract and is chosen based on the drug's physicochemical properties, solubility, and the release mechanism of the dosage form.

2.4 Common Media

Water: Used for water-soluble drugs.

Simulated Gastric Fluid (SGF): Typically consists of 0.1 N hydrochloric acid (HCl) with or without enzymes. This medium simulates the acidic environment of the stomach (pH 1.2).

Simulated Intestinal Fluid (SIF): Contains buffer solutions (such as phosphate buffers) with a pH of 6.8 to mimic the intestinal environment.

Other Buffers: Phosphate buffers at various pH levels (e.g., pH 4.5 for weak acids) are commonly used.

Surfactants: Added to increase the solubility of poorly water-soluble drugs (e.g., sodium lauryl sulfate).

2.5 Volume of Dissolution Medium

Typical Volume: The standard volume is 900 mL for most dissolution tests. However, this may be adjusted based on the sink conditions or dosage form.

Sink Conditions: The dissolution medium should maintain sink conditions to ensure that the drug's solubility does not limit dissolution. This means the medium volume should be sufficient to dissolve at least three times the amount of drug present in the dosage form.

3 Sampling Techniques

Sampling during dissolution testing is carried out at specific intervals to measure the concentration of the drug released into the medium. This is essential for generating a dissolution profile that tracks how much drug is released over time.

3.4 Manual Sampling

Process: Samples are withdrawn manually at predetermined time intervals using a syringe or pipette. Care must be taken to ensure the dosage form is not disturbed.

Filtering: Immediately after withdrawal, the sample is often filtered to remove any undissolved particles.

3.5 Automated Sampling

Process: Automated systems allow for continuous or interval-based sampling without manual intervention. These systems are integrated with analytical devices for immediate analysis.

Advantages: They reduce variability, improve reproducibility, and streamline the dissolution testing process.

4 Analytical Methods

Once samples are collected from the dissolution vessel, they must be analyzed to determine the concentration of dissolved drug. Two primary analytical techniques are used:

4.4 UV-Visible Spectrophotometry

Principle: Measures the absorbance of UV or visible light by the dissolved drug at a specific wavelength. This absorbance is directly related to the concentration of the drug in the solution (following Beer-Lambert Law).

Advantages: It is a simple, cost-effective, and rapid method for determining drug concentration in solution.

Limitations: UV-Vis spectrophotometry may not be suitable for drugs that absorb light at similar wavelengths as excipients or dissolution media components.

4.5 High-Performance Liquid Chromatography (HPLC)

Principle: HPLC separates the drug from excipients or degradation products based on their interactions with the stationary phase in a chromatographic column.

Advantages: It is highly specific, sensitive, and suitable for complex formulations or drugs with low solubility.Limitations: HPLC requires more resources and time than UV-Vis spectrophotometry but provides superior accuracy and precision.

5 Key Variables in Dissolution Testing

Dissolution testing must account for several variables to ensure accurate, reliable, and reproducible results.

5.4 Agitation Speed

The speed of the basket or paddle significantly impacts the dissolution rate. Higher agitation speeds increase the mixing of the medium, promoting faster dissolution. Typical speeds range from 50 to 100 RPM, with slower speeds often used for modified-release formulations.

5.5 Temperature

Maintaining the dissolution medium at 37°C is crucial to mimic human physiological conditions. Even slight temperature variations can affect the dissolution rate and drug solubility.

5.3 pH of the Dissolution Medium

The pH of the dissolution medium should match the physiological environment the drug will encounter (e.g., acidic for the stomach and neutral for the intestine). Some drugs may require testing at multiple pH levels to simulate the transitions in the GI tract.

5.4 Sample Volume

The sample volume should be carefully controlled, especially in manual sampling. Large withdrawals can alter the concentration of the remaining medium, affecting the dissolution rate.

5.5 Sink Conditions

The dissolution medium must maintain sink conditions to avoid saturation, which could slow the dissolution process. If the drug concentration exceeds solubility, the dissolution rate will artificially plateau.

5.6 Regulatory Requirements and Guidelines

Dissolution testing is a regulatory requirement for drug approval and quality

control. Different pharmacopeias (USP, European Pharmacopeia, Japanese Pharmacopeia) have established standards for dissolution testing, including acceptable ranges for dissolution profiles and test conditions.

Immediate-Release Dosage Forms: Typically, 80% of the drug should dissolve within 30 minutes.Modified-Release Dosage Forms: The dissolution profile should match the intended release mechanism and be tested under varying pH conditions.

Pharmaceutical dosage forms.

1) Parenteral Route

The most common injection routes are intramuscular, intravenous, and subcutaneous, typically providing short-term effects. However, advanced implantable devices have been developed to control drug release, offering a longer duration of action. For accurate in vitro evaluation of drug release from these forms, the dissolution medium should closely match the ion concentration found in human plasma.

2) Oral Route

The oral route is the most common and convenient administration method for the systemic delivery of drugs. It affords high patient acceptability, compliance, and ease of administration. Moreover, the cost of oral therapy is generally much lower than that of parenteral therapy. Nevertheless, the oral route is not without disadvantages, particularly with respect to labile drugs such as peptide- and oligonucleotide-based pharmaceuticals. During the last decades, numerous novel oral drug delivery systems such as mucoadhesives, matrix systems, reservoir systems, microparticulates, and colon-specific drug delivery systems have been developed to overcome some of these limitations.

3)Buccal and Sublingual Route

Localized drug delivery to the mouth is commonly used to treat oral conditions such as aphthous ulcers, fungal infections, and periodontal disease. In addition to targeting these conditions topically, there has been significant interest in using the oral mucosa for transmucosal drug delivery, allowing for systemic absorption through the mucous membranes of the oral cavity.

4)Vaginal Route

Traditionally, vaginal formulations available on the market were primarily intended for localized treatment of various conditions. However, recent advancements in vaginal drug delivery are now focused on systemic delivery of medications such as estrogens, progesterones, and prostaglandins. Emerging technologies are also investigating the potential for delivering therapeutic peptides and proteins systemically through the vaginal route.

Biopharmaceutical classification system (BCS)

The Biopharmaceutical Classification System (BCS) plays a critical role in dissolution testing, as it categorizes drugs based on their solubility and permeability, which directly influences their absorption and bioavailability. The BCS classifies drugs into four categories:

1. BCS Class I (High solubility, high permeability): Drugs in this category are expected to dissolve quickly and be readily absorbed. For these drugs, dissolution testing may be less stringent as in vivo performance is typically predictable.

2. BCS Class II (Low solubility, high permeability): These drugs exhibit limited solubility, which can slow dissolution and affect absorption. Dissolution testing becomes essential for this class to assess how formulation adjustments can improve drug release.
3. BCS Class III (High solubility, low permeability): These drugs dissolve well but have low permeability. Dissolution testing is crucial to ensure rapid drug release, though absorption may remain the limiting factor in bioavailability.

4. BCS Class IV (Low solubility, low permeability): Drugs in this class present significant challenges in both dissolution and absorption. Extensive dissolution testing and formulation innovations are required to enhance bioavailability.

In dissolution testing, the BCS framework aids in predicting a drug's in vivo behavior, optimizing formulations, and establishing bioequivalence. Regulatory agencies often allow biowaivers for BCS Class I and some Class III drugs, meaning that in vivo bioequivalence studies can be waived if dissolution tests show appropriate release profiles. Therefore, the BCS streamlines the drug development process by guiding formulation decisions and improving the efficiency of regulatory assessments.

Bioavailability

Bioavailability refers to the extent and rate at which the active drug ingredient is absorbed from a pharmaceutical product and becomes available in the systemic circulation. In dissolution testing, bioavailability is a crucial aspect because the test is designed to predict how a drug will perform in vivo, particularly how much and how quickly the drug is released and absorbed into the bloodstream.

Dissolution testing evaluates the rate of drug release from solid dosage forms (such as tablets or capsules) into a solution, simulating the gastrointestinal environment. For a drug to be bioavailable, it must first dissolve in gastrointestinal fluids before it can be absorbed. Therefore, dissolution testing serves as an indirect measure of bioavailability. The key relationships between bioavailability and dissolution testing include:

1. Prediction of Drug Absorption: Dissolution testing helps predict the rate and extent of drug absorption, particularly for oral dosage forms. The faster and more completely a drug dissolves, the more likely it is to be absorbed effectively, leading to higher bioavailability.
2. Formulation Optimization: Dissolution testing allows formulation scientists to optimize drug formulations by identifying the best conditions for drug release. By adjusting factors such as particle size, excipients, and coatings,

bioavailability can be improved through enhanced dissolution rates.

3. Bioequivalence Studies: Dissolution testing is often used to demonstrate bioequivalence between generic and branded drugs. If two products have similar dissolution profiles, they are more likely to have comparable bioavailability, reducing the need for expensive in vivo studies.
4. Impact of Poor Solubility: For poorly soluble drugs (especially BCS Class II drugs), dissolution is often the rate-limiting step in bioavailability. Improving dissolution rates through advanced formulations or dissolution-enhancing techniques can significantly enhance bioavailability.
5. Biorelevant Dissolution Testing: In some cases, bioavailability is affected by physiological conditions, such as pH or bile salts. Biorelevant dissolution testing, which simulates these conditions, provides a more accurate prediction of in vivo bioavailability, helping to bridge the gap between in vitro tests and in vivo performance.

In summary, dissolution testing plays a pivotal role in assessing and predicting the bioavailability of a drug product. It is a key tool in the development, optimization, and regulation of pharmaceutical products, ensuring that they deliver the intended therapeutic effect efficiently and consistently.

Conclusion

In conclusion, dissolution testing plays a pivotal role in the pharmaceutical industry, serving as a fundamental analytical technique for assessing the release profiles of solid dosage forms and their subsequent bioavailability. The historical evolution of dissolution testing highlights its growing importance in ensuring drug quality, safety, and efficacy, particularly in light of documented cases of bioinequivalence. As a result, regulatory agencies have established stringent guidelines for dissolution testing, making it an integral part of drug development and quality control.

The methodologies employed in dissolution testing, including various USP apparatuses, are designed to accurately simulate in vivo conditions. Each apparatus has specific applications tailored to different formulations, enabling scientists to evaluate how a drug is released from its dosage form. The selection of dissolution media is equally critical, as it must closely mimic the physiological conditions encountered in the gastrointestinal tract, thus providing relevant insights into drug absorption and effectiveness.

Moreover, the understanding of key variables—such as agitation speed, temperature, pH, sample volume, and sink conditions—is essential for generating reliable and reproducible results. With advancements in analytical techniques like UV-Visible Spectrophotometry and High-Performance Liquid Chromatography (HPLC), researchers can obtain precise measurements of drug concentration over time, further enhancing the utility of dissolution testing.

The Biopharmaceutical Classification System (BCS) serves as a valuable framework for categorizing drugs based on their solubility and permeability, influencing dissolution testing strategies. This classification is particularly pertinent for BCS Class II and III drugs, where dissolution characteristics play a critical role in predicting in vivo performance and guiding formulation development.

Despite its established importance, challenges remain in enhancing dissolution methods to better simulate in vivo conditions and address the complexities of novel drug delivery systems. Ongoing research and innovation are necessary to refine these methodologies and improve our understanding of dissolution's role in drug absorption. The future of dissolution testing lies in the integration of biorelevant media and advanced analytical techniques that can more accurately reflect physiological environments, ultimately ensuring that pharmaceutical products meet their intended therapeutic outcomes.

In summary, dissolution testing is a cornerstone of pharmaceutical science, essential for maintaining the quality and efficacy of drug products. As the field continues to evolve, so too will the methodologies and standards that govern dissolution testing, reinforcing its critical role in the safe and effective delivery of medications to patients.

Reference

1. Noyes, A. A.; Whitney, W. R. The Rate of Solution of Solid Substances in Their Own Solutions. J. Am. Chem. Soc. 1897, 19, 930–934. DOI: 10.1021/ja02086a003.

2. Edwards, L. J. The dissolution and diffusion of aspirin in aqueous media. Trans. Faraday Soc. 1951, 47, 1191– 1210. DOI: 10.1039/TF9514701191.

3. Nelson, E. Solution rate of theophylline salts and effects from oral administration. J. Am. Pharm. Assoc. 1957, 46 (10), 607–614. DOI: 10.1002/jps.3030461012.

4. Levy, G. Effect of Dosage Form Properties on Therapeutic Efficacy of Tolbutamide Tablets. Can. Med. Assoc. J. 1964, 90, 978–979.

5. Martin, C. M.; Rubin, M.; O'Malley, W. G.; Garagusi, V. F.; McCauley, C. E. Brand, generic drugs differ in man. JAMA, J. Am. Med. Assoc. 1968, 205 (1), A23

6.Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists; Hillery, A. M., Lloyd, A. W., Swarbrick, J., Eds.; Taylor & Francis: New York, 2001.

7.Kokubo, T.; Ito, S.; Huang, Z. T.; Hayashi, T.; Sakka, S. Ca,P-rich layer formed on high-strength bioactive Glass-ceramic A-W. J. Biomed. Mater. Res. 1990, 24 (3), 331–343.

8.Cho, S. B.; Nakanishi, K.; Kokubo, T.; Soga, N.; Ohtsuki, C.; Nakamura, T. Apatite formation on silica gel in simu- Lated body fluid: its dependence on structures of silica Gels prepared in different media. J. Biomed. Mater. Res. 1996, 33 (3), 145–151.

9.Cho, S. B.; Nakanishi, K.; Kokubo, T.; Soga, N.; Ohtsuki, C.; Nakamura, T.; Kitsugi, T.; Yamamuro, T. Dependence of Apatite formation on silica gel on its structure: effect Of heat treatment. J. Am. Ceram. Soc. 1995, 78 (7), 1769–1774.

10.Kokubo, T.; Takadama, H. How useful is SBF in predicting In vivo bone bioactivity? Biomaterials 2006, 27 (15), 2907–2915.

11. Banakar UV, Block LH. Beyond bio- Availability testing. Pharm Technol 1983; 7: 107–117.

12.LöbenbergRet al.Dissolutiontestingas A prognostic tool for oral drug absorp- Tion: dissolution behavior of gliben- Clamide.Pharm Res 2000; 17: 439–444.

13.Dyas AM, Shah UU. Dissolution and Dissolution testing. In: Swarbrick J, Ed. Encyclopedia of Pharmaceutical Technology, Vol. 1, 3rd edn. New

York: Informa Healthcare USA, Inc., 2007: 908–928.

14.Dressman JB et al. Dissolution testing As a prognostic tool for oral drug Absorption: immediate release dosage Forms. Pharm Res 1998;

15: 11–22. 15.Shah VP, Williams RL. Roles of disso-Lution testing: regulatory, industry And academic perspectives: role of dis- Solution testing in regulating pharma- Ceuticals. Dissolution Technol 1999; 8:7-10